Every Form 4 that INTENSITY THERAPEUTICS INC (INTS) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow INTS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INTS filings page.
Intensity Therapeutics, Inc. reported that director Thomas I H Dubin was granted a stock option to acquire 5,500 shares of Common Stock at an exercise price of $4.90 per share. The option expires on July 16, 2036 and will vest in four equal annual installments beginning July 16, 2026, subject to his continued service with the company. Following this grant, he directly holds options for 5,500 shares.
Intensity Therapeutics director Donovan Daniel received a stock option grant for 5,500 shares of common stock on July 16, 2026. The option has an exercise price of $4.90 per share, expires on July 16, 2036, and vests in four equal annual installments starting July 16, 2026, subject to continued service.
Intensity Therapeutics, Inc. director Mark A. Goldberg received a grant of stock options covering 5,500 shares of common stock. The options have an exercise price of $4.90 per share, expire on 2036-07-16, and are held directly. They will vest in four equal annual installments beginning on July 16, 2026, subject to his continued service.
Intensity Therapeutics, Inc. reported that director Emer Leahy received a grant of stock options covering 5,500 shares of common stock at an exercise price of $4.90 per share. The options vest in four equal annual installments beginning July 16, 2026, subject to continued service, and expire July 16, 2036, leaving Leahy with options on 5,500 shares in total.
Intensity Therapeutics, Inc. reported an option grant to Principal Accounting Officer John M. Wesolowski for 11,000 stock options to buy common stock at an exercise price of $4.90 per share. The options vest in four equal annual installments beginning July 16, 2027 and expire July 16, 2036.
Intensity Therapeutics granted its Chief Financial Officer, Joseph Talamo, a stock option for 34,000 shares of Common Stock on July 16, 2026. The option has a $4.90 per-share exercise price and expires on July 16, 2036.
According to the terms, the option will vest in four equal annual installments beginning July 16, 2027, conditioned on his continued service with the company. Following this grant, Talamo holds 34,000 stock options directly.
Intensity Therapeutics, Inc. reported that President and CEO Lewis H. Bender received a grant of 78,000 stock options on July 16, 2026. The options carry an exercise price of $4.90 per share and expire on July 16, 2036. They vest in four equal annual installments beginning July 16, 2026, subject to his continued service, and represent an acquisition of derivative securities rather than a market purchase or sale of common stock.
INTENSITY THERAPEUTICS, INC. Principal Accounting Officer John M. Wesolowski acquired 3,688 shares of common stock on an exempt basis through the company’s Amended and Restated 2024 Employee Stock Purchase Plan. The shares were purchased at $3.485 each, bringing his direct holdings to 7,102 shares.
Under the plan, the purchase price equaled 85% of the closing price of the common stock on June 30, 2026. All share amounts reported reflect a 1-for-25 reverse split of the company’s common stock that became effective on February 18, 2026.
INTENSITY THERAPEUTICS, INC. Chief Financial Officer Joseph Talamo acquired 1,093 shares of common stock through the company’s Amended and Restated 2024 Employee Stock Purchase Plan. The shares were purchased at $3.485 per share, equal to 85% of the June 30, 2026 closing price, bringing his direct holdings to 2,239 shares after a prior 1-for-25 reverse split adjustment.
BENDER LEWIS H reported acquisition or exercise transactions in this Form 4 filing.
INTENSITY THERAPEUTICS, INC. President and CEO Lewis H. Bender received a grant of 37,749 shares of common stock at $6.11 per share as a fully vested stock award under the company’s 2021 Stock Incentive Plan. The award was made in partial satisfaction of his 2025 bonus, in lieu of cash, at his request. Following this grant, he holds 118,549 common shares directly, with all amounts adjusted for a 1-for-25 reverse stock split effected on February 18, 2026.